Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Human Cell Line Produces High-Quality RSV for Vaccine Production

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Cooperation between German and American biotechnology companies may pave the way for development of a vaccine to prevent RSV (respiratory syncytial virus) respiratory infections, which have been estimated to cause nearly 7% of the deaths of infants that die during their first year of life.

The companies involved are CEVEC Pharmaceuticals (Cologne, Germany), a clinical stage pharmaceutical company focusing on the development of highly potent protein and vaccine expression systems based on human CAP cells and Paragon Bioservices Inc. (Baltimore, MD, USA), a leading American biopharmaceutical contract manufacturer.

CEVEC has developed a new and proprietary expression system for biopharmaceuticals offering significant advantages over existing production technologies. Their CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards. CEVEC´s CAP cells have proven highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. These molecules are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Their ability to generate human glycosylation patterns also makes CAP cells a valuable tool for vaccine production.

The CEVEC/Paragon project has succeeded in producing RSV in CAP cells that show a high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

"Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines," said Dr. Rainer Lichtenberger, COO of CEVEC. "Next to Cytomegalovirus, influenza, and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful."

Marco Chacón, CEO of Paragon said, "This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business."

Related Links:

CEVEC Pharmaceuticals
Paragon Bioservices Inc.



comments powered by Disqus

Channels

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.